{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric, a specific numeric value for that metric, and a unit for that value. The text primarily describes methods, calculations, and results in general terms, without providing specific numeric values with units for bioactivity metrics."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe half-maximal inhibitory concentration (IC50) values were calculated by non-linear regression using sigmoidal concentration response (variable slope) in XLfit 4 (IDBS, UK) with ten concentrations covering 50 pM to 1 \u03bcM in a 3-fold dilution curve.\n* antibody too weak to fit a dose-response curve, 6% inhibition at 1 \u03bcM.\n** control (ctrl) antibody too weak to fir a dose-response curve, 37% inhibition at 1 \u03bcM."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": "pM - \u03bcM", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": "6%", "unit": "%", "is_logarithmic": false}, {"molecule_name": "ctrl antibody", "protein_target_name": null, "binding_metric": null, "value": "37%", "unit": "%", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nMice were injected with 45 (n=5) or control (n=3) antibody sc at a dose of 10 mg/kg.\nMice were treated twice a week with 10 mg/kg of 45 and control antibody (Anti-Hel).\nDifferent doses (4 doses: 0.1, 0.4, 2 and 10 mg/kg) of the Sortilin (45) and control antibodies (Anti-Hel) were injected and mice were sacrificed on day 2."}
{"final_json": [{"molecule_name": "45", "protein_target_name": "Sortilin", "binding_metric": null, "value": "10", "unit": "mg/kg", "is_logarithmic": false}, {"molecule_name": "Anti-Hel", "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "mg/kg", "is_logarithmic": false}]}
{"raw_mentions": "An anti-Sortilin antibody that binds to the Sortilin D Region will usually bind to a conformational epitope or a linear epitope of 3, 4, 5, 6 or 7 consecutive amino acids within the D-Region (for example SEQ ID NOs:185, 186 or 187) with an affinity (IC50) at or below 22 nM, such as between 22 nM and 1 nM, between 10 nM and 1 nM or between 5 nM and 1 nM."}
{"final_json": [{"molecule_name": "anti-Sortilin antibody", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": "at or below 22", "unit": "nM", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. In particular, the invention pertains to anti-Sortilin antibodies that exhibit a binding affinity corresponding to at or below 22 nM, such as between 22 nM and 1 nM, between 10 nM and 1 nM or between 5 nM and 1 nM, when determined by, for instance, bioLayer interferometry using an Octet 384RED (Example 8).\n2. The term \u201ccapability to reduce and/or inhibit PGRN binding to Sortilin\u201d includes an antibody that has the ability to inhibit binding to PGRN at an IC50 less than 50 nM but preferably between 10 nM and 0.2 nM using a time resolved fluorescence assay (HTFR) disclosed in Example 10.\n3. In one embodiment, the invention relates to an antibody, or antigen-binding fragment thereof, which exhibits one or more of the following properties: (i) a binding affinity (KD) for Sortilin of between 0.5-10 nM, such as 1-5 nM or 1-2 nM; \n4. As used herein, the term \u201cbinding\u201d in the context of the binding of an antibody to a predetermined antigen typically refers to binding with an affinity corresponding to a KD of about 10\u22127 M or less, such as about 10\u22128 M or less, such as about 10\u22129 M or less when determined by for instance surface plasmon resonance (SPR) technology in either a BIAcore\u00ae 3000 or T200 instrument using the antigen as the ligand and the antibody as the analyte, and binds to the predetermined antigen with an affinity corresponding to a KD that is at least ten-fold lower, such as at least 100 fold lower, for instance at least 1,000 fold lower, such as at least 10,000 fold lower, for instance at least 100,000 fold lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen."}
{"final_json": [{"molecule_name": "anti-Sortilin antibodies", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": "22", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": "PGRN", "binding_metric": "IC50", "value": "< 50", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody, or antigen-binding fragment thereof", "protein_target_name": "Sortilin", "binding_metric": "KD", "value": "0.5-10", "unit": "nM", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "predetermined antigen", "binding_metric": "KD", "value": "10\u22127", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "non-specific antigen (e.g., BSA, casein)", "binding_metric": "KD", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, IDs, or other identifiers along with bioactivity metrics, numeric values, and units. The text primarily describes methods, preparations, and functionalities of anti-Sortilin antibodies in general terms without providing specific data."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n7. The antibody, or antigen-binding fragment thereof, according to any preceding Embodiment, wherein the antibody or antigen-binding fragment exhibits one or more of the following properties: (i) a binding affinity (KD) for Sortilin of between 0.5-10 nM, such as 1-5 nM or 1-2 nM\n9. The antibody, or antigen-binding fragment thereof, according to Embodiment 7 or 8, wherein the capability of said antibody or fragment thereof the antibody or fragment thereof to reduce and/or inhibit PGRN binding to Sortilin comprises reducing and/or inhibiting PGRN binding to Sortilin with an IC50 at or below 22 nM, such as between 22 nM and 1 nM, or between 10 nM and 1 nM, or between 5 nM and 1 nM."}
{"final_json": [{"molecule_name": "antibody or antigen-binding fragment", "protein_target_name": "Sortilin", "binding_metric": "KD", "value": "0.5-10", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody or fragment thereof", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": "22", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody or fragment thereof", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": "1", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody or fragment thereof", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": "10-1", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody or fragment thereof", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": "5-1", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody or antigen-binding fragment", "protein_target_name": "Sortilin", "binding_metric": "KD", "value": "1-5", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "antibody or antigen-binding fragment", "protein_target_name": "Sortilin", "binding_metric": "KD", "value": "1-2", "unit": "nM", "is_logarithmic": false}]}
{"raw_mentions": "None of the sentences in the provided text meet the specified criteria as they do not contain a specific molecule name, ID, or other identifier along with a bioactivity metric, a specific numeric value for that metric, and a unit for that value. The text primarily discusses embodiments of nucleic acid molecules, vectors, host cells, methods for producing antibodies, and preparations or compositions of antibodies for various medical uses, without providing specific bioactivity data."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe IC50 for the Sortilin specific compound AF38469 (Schr\u00f8der et al, Bioorg Med Chem Lett. 2014 Jan. 1; 24(1):177-80, 2014) was determined by measuring the displacement of <sup>3</sup>H-Neurotensin binding to Sortilin using a scintillation proximity assay (SPA).\nIC50 values for antibodies were determined by measuring the displacement of PGRN binding to Sortilin using a homogenous time resolved fluorescent (HTRF, CisBio) assay, see FIG. 5 and FIG. 6.\nDose-response evaluation of antibodies was performed with ten concentrations between 1 \u03bcM and 50 pM in a 3-fold dilution curve.\nDose-response evaluation for AF38469 was performed with ten concentrations between 50 \u03bcM and 2.5 nM in a 3-fold dilution curve."}
{"final_json": [{"molecule_name": "AF38469", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "antibodies", "protein_target_name": "Sortilin", "binding_metric": "IC50", "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "antibodies", "protein_target_name": null, "binding_metric": null, "value": "1 \u03bcM", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "antibodies", "protein_target_name": null, "binding_metric": null, "value": "50 pM", "unit": "pM", "is_logarithmic": false}, {"molecule_name": "AF38469", "protein_target_name": null, "binding_metric": null, "value": "50 \u03bcM", "unit": "\u03bcM", "is_logarithmic": false}, {"molecule_name": "AF38469", "protein_target_name": null, "binding_metric": null, "value": "2.5 nM", "unit": "nM", "is_logarithmic": false}]}
{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric, a specific numeric value for that metric, and a unit for that value. The text primarily discusses experimental methods, results, and observations without providing specific bioactivity metrics with numeric values and units."}
